黄萱益肝散联合复方牛胎肝提取物片治疗慢性乙型肝炎肝纤维化的疗效观察  

Clinical observation of Huangxuan Yigan Powder combined with Compound Embryonic Bovine Liver Extract Tablets in treatment of hepatic fibrosis of chronic hepatitis B

作　　者：独晓勤 孟雪飞 李红兵 DU Xiao-qin;MENG Xue-fei;LI Hong-bing(Department of Infection,Weinan Central Hospital,Weinan 714000,China)

机构地区：[1]渭南市中心医院感染性疾病科,陕西渭南714000

出　　处：《现代药物与临床》2018年第12期3302-3305,共4页Drugs & Clinic

摘　　要：目的探讨黄萱益肝散联合复方牛胎肝提取物片治疗慢性乙型肝炎肝纤维化的临床疗效。方法选取2015年5月—2017年5月在渭南市中心医院治疗的慢性乙型肝炎肝纤维化患者80例,根据用药差别分为对照组(40例)和治疗组(40例)。对照组口服复方牛胎肝提取物片,80 mg/次,3次/d。治疗组在对照组基础上口服黄萱益肝散,9 g/次,3次/d。两组患者均治疗48周。观察两组患者临床疗效,同时比较治疗前后两组患者肝功能指标、肝纤维化指标、CLDQ量表和SF-36量表评分。结果治疗后,对照组临床有效率为80.00%,显著低于治疗组的97.50%,两组比较差异具有统计学意义(P<0.05)。治疗24、48周后,两组患者丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、总胆汁酸(TBA)均比治疗前明显降低(P<0.05),且治疗组ALT、AST、TBIL和TBA水平明显低于同期对照组(P<0.05)。治疗24、48周后,两组血清透明质酸(HA)、三型前胶原N端肽(PC-III)、四型胶原(IV-C)、层黏连蛋白(LN)均显著降低(P<0.05),且治疗组上述肝纤维化指标水平明显低于同期对照组(P<0.05)。治疗24、48周后,两组患者CLDQ量表和SF-36量表评分均明显升高(P<0.05),且治疗组CLDQ量表和SF-36量表评分明显高于同期对照组(P<0.05)。结论黄萱益肝散联合复方牛胎肝提取物片治疗慢性乙型肝炎肝纤维化可有效改善患者肝功能,降低机体炎性因子和肝纤维化指标水平,提高患者生活质量,具有一定的临床推广应用价值。Objective To investigate the clinical efficacy of Huangxuan Yigan Powder combined with Compound Embryonic Bovine Liver Extract Tablets in treatment of hepatic fibrosis of chronic hepatitis B. Methods Patients(80 cases) with hepatic fibrosis of chronic hepatitis B in Weinan Central Hospital from May 2015 to May 2017 were divided into control(40 cases) and treatment(40 cases) groups based on different treatments. Patients in the control group were po administered with Compound Embryonic Bovine Liver Extract Tablets, 80 mg/time, three times daily. Patients in the treatment group were po administered with Huangxuan Yigan Powder on the basis of the control group, 9 g/time, three times daily. Patients in two groups were treated for 48 weeks. After treatment, the clinical efficacy was evaluated, and the liver function indexes, the liver fibrosis indexes, the CLDQ scale and SF-36 scale scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.00%, which was significantly lower than 97.50% in the treatment group, and there were differences between two groups(P < 0.05). After treatment for 24 and 48 weeks, the ALT, AST, TBIL, and TBA levels in two groups were significantly decreased(P < 0.05), and the ALT, AST, TBIL and TBA levels in the treatment group were significantly lower than those in the control group at the same period(P < 0.05). After treatment for 24 and 48 weeks, the HA, LN, PC-Ⅲ, and Ⅳ-C levels in two groups were significantly decreased(P < 0.05), and the liver fibrosis indexes in the treatment group were significantly lower than those in the control group of the same period(P < 0.05). After treatment for 24, 48 weeks, the CLDQ and SF-36 scores in two groups were significantly increased(P < 0.05), and these scores in the treatment group were significantly higher than those in the control group of the same period(P < 0.05). Conclusion Huangxuan Yigan Powder combined with Compound Embryonic Bovine Liver Extract Tablets in treatme

关 键 词：黄萱益肝散 复方牛胎肝提取物片 慢性乙型肝炎 肝纤维化 丙氨酸氨基转移酶 总胆红素 透明质酸 层黏连蛋白 

分 类 号：R978.7[医药卫生—药品]